Issues in the Design and Conduct of Clinical Trials

References

• Bell R. L., Smith E. O. “Clinical Trials in Post-Marketing Surveillance of Drugs,”. Controlled Clin Trials 1982; 3: 61
   PubMedGoogle Scholar
• Brown B.W., Jr. “Statistical Controversies in the Design of Clinical Trials: Some Personal Views,”. Controlled Clin Trials 1980; 1: 13
   Google Scholar
• Cassileth R. B., Luck E. J., Miller D. S., Hurwitz S. “Attitudes Toward Clinical Trials Among Patients and the Public,”. J Amer Med Assoc 1982; 248: 968
   PubMed Web of Science ®Google Scholar
• Chalmers T. C., et al. “A Method for Assessing the Quality of a Randomized Control Trial,”. Controlled Clin Trials 1981; 2: 31
   PubMedGoogle Scholar
• Cornfield J. “Recent Methodological Contributions to Clinical Trials,”. Am J Epidemiol 1976; 104: 408
   PubMed Web of Science ®Google Scholar
• Cuzick J. “The Assessment of Subgroups in Clinical Trials,”. Experientia 1982; 41, Suppl.), 224(.
   PubMedGoogle Scholar
• Dersimonian R., Charette L. J., McPeek B., Mosteller F. “Reporting on Methods in Clinical Trials,”. New Eng J Med 1982; 306: 1332
   PubMed Web of Science ®Google Scholar
• Diamond G. A., Forrester J. S. “Clinical Trials and Statistical Verdicts: Probable Grounds for Appeal,”. Ann Intern Med 1983; 98: 385
   PubMed Web of Science ®Google Scholar
• Dunbar J., et al. “Organization and Management of Recruitment,”. Circulation 1982; 66, Suppl, 49
   PubMed Web of Science ®Google Scholar
• Feinstein A. R. “Problems and Challenges in Randomized Trials: A Commentary,”. Triangle 1980; 19: 77
   PubMedGoogle Scholar
• Freedman L. S. “Stopping Rules for Clinical Trials,”. Stat Med 1983; 2: 167
   PubMedGoogle Scholar
• Freiman J. A., Chalmers T. C., Smith H., Jr., Kuebler R. R. “The Importance of Beta, The Type II Error and Sample Size in the Design and Interpretation of the Randomized Control Trial,” New. Eng J Med 1978; 299: 690
   PubMed Web of Science ®Google Scholar
• Friedman L. M., Furberg CD., Demets D. L. Fundamentals of Clinical Trials. John Wright PSG Inc., Littleton, MA 1981
   Google Scholar
• Hemminki E. “Quality of Clinical Trials - A Concern of Three Decades,”. Meth Inform Med 1982; 21: 81
   PubMed Web of Science ®Google Scholar
• Hill G. B. “Controlled Clinical Trials - The Emergence of a Paradigm, ”. Clin Invest Med 1983; 6: 25
   PubMed Web of Science ®Google Scholar
• Kinney E. L., et al. “Underrepresentation of Women in New Drug Trials,”. Ann Intern Med 1981; 95: 495
   PubMed Web of Science ®Google Scholar
• Lebacqz K. “Controlled Clinical Trials: Some Ethical Issues,”. Controlled Clin Trials 1980; 1: 29
   PubMedGoogle Scholar
• Meinert C. L. “Toward More Definitive Clinical Trials,”. Controlled Clin Trials 1980; 1: 249
   PubMedGoogle Scholar
• Meinert C. L. “Funding for Clinical Trials,”. Controlled Clin Trials 1982; 3: 165
   PubMedGoogle Scholar
• Peto R., et al. “Design and Analysis of Randomized Clinical Trials Requiring Prolonged Observation of Each Patient: I. Introduction and Design,”. Br J Cancer 1976; 34: 585
   PubMed Web of Science ®Google Scholar
• Peto R., et al. “Design and Analysis of Randomized Clinical Trials Requiring Prolonged Observation of Each Patient; II. Analysis and Examples,”. Br J Cancer 1977; 35: 1
   PubMed Web of Science ®Google Scholar
• Pocock S. J. “Allocation of Patients to Treatment in Clinical Trials,”. Biometrics 1979; 35: 183
   PubMed Web of Science ®Google Scholar
• Sackett D. L., Gent J. “Controversy in Counting and Attributing Events in Clinical Trials,”. New Eng J Med 1979; 301: 1410
   PubMed Web of Science ®Google Scholar
• Sacks H., Chalmers T. C., Smith H., Jr. “Randomized Versus Historical Controls for Clinical Trials,”. Am J Med 1982; 72: 233
   PubMed Web of Science ®Google Scholar
• Schafer A. “The Ethics of the Randomized Clinical Trial,”. New Eng J Med 1982; 307: 719
   PubMed Web of Science ®Google Scholar
• Schoenbaum S. C. “Cost/Effectiveness Considerations in Clinical Trials,”. Triangle 1980; 19: 103
   PubMedGoogle Scholar
• Clinical Trials, Issues and Approaches, S. H. Shapiro, T. A. Louis. Marcel Dekker, New York 1983
   Google Scholar
• Spilker B. “Practical Considerations in Planning and Conducting Clinical Trials with Investigational or Marketed Drugs,”. Clin Neuropharmacol 1983; 6: 325
   PubMed Web of Science ®Google Scholar
• Spodick H. D. “The Randomized Controlled Clinical Trial: Scientific and Ethical Bases,”. Am J Med 1982; 73: 420
   PubMed Web of Science ®Google Scholar
• Spodick D. H. “Randomized Controlled Clinical Trials: The Behavioral Case,”. J Amer Med Assoc 1982; 247: 2258
   PubMed Web of Science ®Google Scholar
• Tygstrup N. “Principles and Problems of Clinical Trials: A Europeal View,”. Triangle 1980; 19: 93
   PubMedGoogle Scholar
• Uberla K. K. “Randomized Clinical Trials: Why Not?”. Controlled Clin Trials 1981; 1: 295
   PubMedGoogle Scholar
• Vere D. W. “Logic and Inference in Clinical Trials,”. Br J Clin Pharmacol 1982; 14: 171
   PubMed Web of Science ®Google Scholar
• Weiss D. G., et al. “Planning Multicenter Clinical Trials: A Biostatistician's Perspective,”. Controlled Clin Trials 1983; 4: 53
   PubMedGoogle Scholar
• Zelen M. “A New Design for Randomized Clinical Trials,”. New Eng J Med 1979; 300: 1242
   PubMed Web of Science ®Google Scholar